Hikari Power’s Aimmune Therapeutics AIMT Stock Holding History

Hikari Power’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-30,000	Closed	-$617K	–	102
2017 Q2	$617K	Buy	+30,000	New	+$572K	0.08%	59

Other funds holding AIMT

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

TLP Group Evanston, Illinois $6.61M AUM 12.46% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Hikari Power's AIMT Position: Q3 2017 in Review

Hikari Power sold out of Aimmune Therapeutics (AIMT) in Q3 2017, closing a stake of 30,000 shares — an estimated $617K sold.

Hikari Power first reported a position in AIMT in Q2 2017 and held it in 1 quarter. The position peaked at $617K in Q2 2017. 100 funds tracked by Wall St. Rank hold AIMT as of Q3 2017.

Hikari Power reported no remaining Aimmune Therapeutics position as of Q3 2017 after selling out during the quarter.
Hikari Power sold 30,000 Aimmune Therapeutics shares in Q3 2017, an estimated $617K.
Hikari Power first reported a position in Aimmune Therapeutics in Q2 2017 and held it in 1 quarter.
Hikari Power's Aimmune Therapeutics position peaked at $617K in Q2 2017.
100 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2017.

Based on Hikari Power's 13F filing for Q3 2017, filed 8 Nov 2017.